Your browser doesn't support javascript.
loading
Differences and Similarities in the Pattern of Early Metabolic and Morphologic Response after Induction Chemo-Immunotherapy versus Induction Chemotherapy Alone in Locally Advanced Squamous Cell Head and Neck Cancer.
Beck, Michael; Semrau, Sabine; Haderlein, Marlen; Gostian, Antoniu-Oreste; Hartwich, Julius; Müller, Sarina; Kallies, Annett; Geppert, Carol-Immanuel; Schonath, Miriam; Putz, Florian; Gaipl, Udo; Frey, Benjamin; Saake, Marc; Iro, Heinrich; Uder, Michael; Hartmann, Arndt; Kuwert, Torsten; Fietkau, Rainer; Eckstein, Markus; Hecht, Markus.
Afiliación
  • Beck M; Clinic of Nuclear Medicine, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Bavaria, Germany.
  • Semrau S; Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Bavaria, Germany.
  • Haderlein M; Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Bavaria, Germany.
  • Gostian AO; Department of Otolaryngology-Head & Neck Surgery, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Bavaria, Germany.
  • Hartwich J; Clinic of Nuclear Medicine, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Bavaria, Germany.
  • Müller S; Department of Otolaryngology-Head & Neck Surgery, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Bavaria, Germany.
  • Kallies A; Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Bavaria, Germany.
  • Geppert CI; Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Bavaria, Germany.
  • Schonath M; Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Bavaria, Germany.
  • Putz F; Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Bavaria, Germany.
  • Gaipl U; Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Bavaria, Germany.
  • Frey B; Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Bavaria, Germany.
  • Saake M; Department of Diagnostic Radiology, University Hospital of Erlangen, 91054 Erlangen, Bavaria, Germany.
  • Iro H; Department of Otolaryngology-Head & Neck Surgery, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Bavaria, Germany.
  • Uder M; Department of Diagnostic Radiology, University Hospital of Erlangen, 91054 Erlangen, Bavaria, Germany.
  • Hartmann A; Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Bavaria, Germany.
  • Kuwert T; Clinic of Nuclear Medicine, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Bavaria, Germany.
  • Fietkau R; Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Bavaria, Germany.
  • Eckstein M; Institute of Pathology, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Bavaria, Germany.
  • Hecht M; Department of Radiation Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Bavaria, Germany.
Cancers (Basel) ; 14(19)2022 Sep 30.
Article en En | MEDLINE | ID: mdl-36230733
Background: In head and neck cancer patients, parameters of metabolic and morphologic response of the tumor to single-cycle induction chemotherapy (IC) with docetaxel, cis- or carboplatin are used to decide the further course of treatment. This study investigated the effect of adding a double immune checkpoint blockade (DICB) of tremelimumab and durvalumab to IC on imaging parameters and their significance with regard to tumor cell remission. Methods: Response variables of 53 patients treated with IC+DICB (ICIT) were compared with those of 104 who received IC alone. Three weeks after one cycle, pathologic and, in some cases, clinical and endoscopic primary tumor responses were evaluated and correlated with a change in 18F-FDG PET and CT/MRI-based maximum-standardized uptake values (SUVmax) before (SUVmaxpre), after treatment (SUVmaxpost) and residually (resSUVmax in % of SUVmaxpre), and in maximum tumor diameter (Dmax) before (Dmaxpre) and after treatment (Dmaxpost) and residually (resD). Results: Reduction of SUVmax and Dmax occurred in both groups; values were SUVmaxpre: 14.4, SUVmaxpost: 6.6, Dmaxpre: 30 mm and Dmaxpost: 23 mm for ICIT versus SUVmaxpre: 16.5, SUVmaxpost: 6.4, Dmaxpre: 21 mm, and Dmaxpost: 16 mm for IC alone (all p < 0.05). ResSUVmax was the best predictor of complete response (IC: AUC: 0.77; ICIT: AUC: 0.76). Metabolic responders with resSUVmax ≤ 40% tended to have a higher rate of CR to ICIT (88%; n = 15/17) than to IC (65%; n = 30/46; p = 0.11). Of the metabolic nonresponders (resSUVmax > 80%), 33% (n = 5/15) achieved a clinical CR to ICIT versus 6% (n = 1/15) to IC (p = 0.01). Conclusions: ICIT and IC quickly induce a response and 18F-FDG PET is the more accurate modality for identifying complete remission. The rate of discrepant response, i.e., pCR with metabolic nonresponse after ICIT was >30%.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Cancers (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Cancers (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Alemania
...